This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

BELLUS Health Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

BELLUS Health has a total shareholder equity of $368.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $379.5M and $10.6M respectively.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

US$0

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	US$312.99m
Eigenkapital	US$368.90m
Gesamtverbindlichkeiten	US$10.64m
Gesamtvermögen	US$379.54m

Jüngste Berichte zur Finanzlage

BELLUS Health (TSE:BLU) Is In A Good Position To Deliver On Growth Plans

Jan 16

Here's Why We're Not Too Worried About BELLUS Health's (TSE:BLU) Cash Burn Situation

Sep 07

Recent updates

BELLUS Health (TSE:BLU) Is In A Good Position To Deliver On Growth Plans

Jan 16

Here's Why We're Not Too Worried About BELLUS Health's (TSE:BLU) Cash Burn Situation

Sep 07

We're Hopeful That BELLUS Health (TSE:BLU) Will Use Its Cash Wisely

May 05

Here's Why We're Watching BELLUS Health's (TSE:BLU) Cash Burn Situation

Jan 06

Companies Like BELLUS Health (TSE:BLU) Are In A Position To Invest In Growth

Sep 10

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: BLU's short term assets ($327.7M) exceed its short term liabilities ($9.8M).

Langfristige Verbindlichkeiten: BLU's short term assets ($327.7M) exceed its long term liabilities ($834.0K).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: BLU is debt free.

Schulden abbauen: BLU had no debt 5 years ago.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: BLU has sufficient cash runway for more than 3 years based on its current free cash flow.

Vorhersage Cash Runway: BLU has sufficient cash runway for 2.5 years if free cash flow continues to reduce at historical rates of 45.4% each year.

This company has been acquired

BELLUS Health Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

BELLUS Health (TSE:BLU) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About BELLUS Health's (TSE:BLU) Cash Burn Situation

We're Hopeful That BELLUS Health (TSE:BLU) Will Use Its Cash Wisely

Here's Why We're Watching BELLUS Health's (TSE:BLU) Cash Burn Situation

Companies Like BELLUS Health (TSE:BLU) Are In A Position To Invest In Growth

Recent updates

BELLUS Health Inc.(NasdaqGS:BLU) dropped from NASDAQ Composite Index

GSK plc (LSE:GSK) completed the acquisition of BELLUS Health Inc. (TSX:BLU).

President exercised options to buy CA$35m worth of stock.

Consensus revenue estimates increase by 40%, EPS downgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates decrease by 22%, EPS upgraded

Price target decreased by 30% to CA$14.75

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

BELLUS Health (TSE:BLU) Is In A Good Position To Deliver On Growth Plans

Insufficient new directors

Independent Lead Director recently sold CA$449k worth of stock

President exercised options and sold CA$3.1m worth of stock

Independent Director recently sold CA$433k worth of stock

Consensus revenue estimates fall by 93%

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Here's Why We're Not Too Worried About BELLUS Health's (TSE:BLU) Cash Burn Situation

First half 2022 earnings released

BELLUS Health Inc. Expects to Initiate A Phase 1 Clinical Trial Investigating A Once-Daily, Extended-Release Formulation of BLU-5937 in the Fourth Quarter of 2022

Bellus Health Inc. Announces Positive End-Of-Phase 2 Meeting with the FDA and Its Calm Phase 3 Program for BLU-5937 in Refractory Chronic Cough

Price target increased to CA$18.50

Consensus revenue estimates increase by 56%

We're Hopeful That BELLUS Health (TSE:BLU) Will Use Its Cash Wisely

Senior Vice President of Finance recently sold CA$576k worth of stock

Chief Scientific Officer recently sold CA$951k worth of stock

BELLUS Health Inc., Annual General Meeting, May 11, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Consensus forecasts updated

Consensus revenue estimates increase by 16%

Here's Why We're Watching BELLUS Health's (TSE:BLU) Cash Burn Situation

Bellus Health Announces Positive Topline Results from Its Phase 2B Soothe Trial of Blu-5937 for the Treatment of Refractory Chronic Cough

Price target increased to CA$16.40

Third quarter 2021 earnings released: US$0.29 loss per share (vs US$0.094 loss in 3Q 2020)

BELLUS Health Inc. Announces Completion of Patient Enrollment in Soothe Phase 2B Trial for Refractory Chronic Cough and Blueprint Phase 2A Trial for Chronic Pruritus Associated with Atopic Dermatitisz

BELLUS Health Announces Positive Interim Analysis from the Phase 2b SOOTHE Trial of BLU-5937 in Refractory Chronic Cough

Price target increased to CA$10.70

Companies Like BELLUS Health (TSE:BLU) Are In A Position To Invest In Growth

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Liquiditätsreserve-Analyse

Entdecken Sie finanziell stabile Unternehmen